Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

New combination of drugs effective against T-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children. The T-ALL form of leukemia that emerges from early T lineage cells has a poorer prognosis than B-lineage ALL. The prognosis for relapsed T-ALL is very poor and new therapies are sorely needed.

20 Jun 2022

Moffitt researchers reveal a mechanism leading to drug resistance in prostate cancer

Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy.

16 Jun 2022

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Researchers determine whether mutations in the Omicron NTD influence its potential to stimulate myeloid cells and enhance inflammatory cytokine release.

22 May 2022

Treatment with imatinib results in lower mortality rates for patients with severe COVID-19

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.

18 May 2022

Scientists identify a way to reverse drug resistance by rewiring the inner workings of leukemia cells

Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukemia cells.

19 Apr 2022

New tactic to disrupt cancer repair mechanism could lead to a potential treatment strategy

While cancer therapies targeting specific genes or disease pathways have extended lives, they can also lead to highly resistant tumors when small reservoirs of cancer cells survive treatment, grow, and spread.

30 Mar 2022

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.

7 Mar 2022

Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release

Researchers investigated the efficacy of two multi-kinase inhibitors, olverembatinib and ponatinib, in inhibiting SARS-CoV-2 omicron-mediated cytokine release in human peripheral blood mononuclear cells.

10 Feb 2022

Study provides atomistic level insight into target residence time of small molecule kinase inhibitors

When a drug molecule binds to its target protein, it stays bound for some time before eventually unbinding the target. The actual time how long a drug molecule resides bound to its target varies among compounds.

29 Jan 2022

Integrin/TGF-β1 inhibitors highly effective in attenuating COVID-19 severity

New study results suggest that integrin inhibitors have the potential to both prevent infection with SARS-CoV-2, including the Delta and Omicron variants, and to decrease TGF-β levels, resulting in a decrease in COVID-19 severity, hospitalization, and death, especially in vulnerable and unvaccinated populations.

5 Jan 2022

Potential association between senescence and aging in COVID-19

A review published in Cells discussed characteristics of cellular senescence and its potential role in COVID-19.

9 Dec 2021

Clearing old, dysfunctional cells in fat alleviates diabetes

Eliminating old, dysfunctional cells in human fat also alleviates signs of diabetes, researchers from UConn Health report. The discovery could lead to new treatments for Type 2 diabetes and other metabolic diseases.

22 Nov 2021

Cycling JAK inhibitors can be effective for treating people with difficult-to-treat rheumatoid arthritis

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with one Janus kinase inhibitor (JAK inhibitor) can achieve success either cycling to other JAKi medications or switching to a biologic drug.

2 Nov 2021

Scientists discover key component of cellular malfunction that contributes to growth of tumors

Scientists have homed in on a crucial step within the sequence of chemical reactions that govern regulation of cell division, proliferation and death, and whose malfunction contributes to the growth of tumors.

2 Nov 2021

Can targeting autophagy become a new approach to COVID-19 treatment?

In a recent review, the author discusses autophagy as a contributing mechanism of selected drugs that are currently being evaluated to treat COVID‐19.

25 Oct 2021

Targeted drug shows promising activity in kidney cancer patients with brain metastases

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.

21 Oct 2021

Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).

2 Oct 2021

Scientists discover novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia

A new type of targeting chaperon protein HSP70 inhibitor QL47 was recently discovered by a team led by Prof. LIU Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences to treat FLT3-ITD-positive acute myeloid leukemia (AML).

27 Sep 2021

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

New computational topology strategy to identify existing medicines for treating COVID-19

Researchers from the ESI International Chair of the CEU Cardenal Herrera University (CEU UCH) and ESI Group have just published in scientific journal Pharmaceutics a new computational topology strategy to identify existing medicines that could be applied to treat COVID-19 without waiting for the research and clinical trial phases required to develop a new medicine.

16 Jun 2021